Torbay Pharmacy Manufacturing Unit appoints md

Dr Nick Frampton to run the unit

The UK’s South Devon Healthcare NHS Foundation Trust has appointed Dr Nick Frampton as managing director of the Torbay Pharmacy Manufacturing Unit (PMU), which produces licensed pharmaceuticals, pharmaceutical specials and medical devices.

Frampton joins the firm from Advanced Medical Solutions Group, where he was vice president of sales and marketing and contributed to a period of double-digit growth. He has formerly held quality, technical and commercial roles at West Pharmaceutical Services, Ernest Jackson and Banner Pharmacaps.

You may also like

Finance
NorthEdge invests in sterile injectable CMO to accelerate international growth

NorthEdge invests in sterile injectable CMO to accelerate international growth

Private equity firm NorthEdge has invested in sterile injectable contract manufacturer and licence holder, Torbay Pharmaceuticals (Torbay), to support its next phase of international growth
Finance
Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal

Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal

The all-stock merger sees Fulcrum rebuild following its pociredir discontinuation, with the combined entity focusing on SLTE-1009 — a monoclonal antibody in development for migraine and headache disorders — funded into 2029
Finance
Prescient completes integration of Uptake and Dolon under single global brand

Prescient completes integration of Uptake and Dolon under single global brand

Prescient Healthcare Group has completed the integration of Uptake and Dolon, creating a 550-strong life sciences consultancy spanning commercial strategy, medical affairs, competitive intelligence and market access
Packaging
Faller Packaging acquires Greek pharma packaging firm Paperpack

Faller Packaging acquires Greek pharma packaging firm Paperpack

Faller Packaging has acquired pharmaceutical packaging specialist Paperpack, expanding its European network and strengthening its presence in South-Eastern Europe
Finance
AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes

AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes

The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming global rights to ACD856 and the NeuroRestore platform
Manufacturing
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows
Research & Development
Digitalisation: more space for research and development in Salzburg, Austria

Digitalisation: more space for research and development in Salzburg, Austria

COPA-DATA is investing €15 million in the project, underlining its long-term commitment to Salzburg and Austria as a location for technology, research and innovation
Subscribe now